Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Current Assets (2017 - 2025)

KalVista Pharmaceuticals' Current Assets history spans 11 years, with the latest figure at $241.7 million for Q2 2025.

  • On a quarterly basis, Current Assets rose 7.09% to $241.7 million in Q2 2025 year-over-year; TTM through Apr 2025 was $241.7 million, a 7.09% increase, with the full-year FY2025 number at $241.7 million, up 7.09% from a year prior.
  • Current Assets hit $241.7 million in Q2 2025 for KalVista Pharmaceuticals, down from $286.0 million in the prior quarter.
  • Over the last five years, Current Assets for KALV hit a ceiling of $286.0 million in Q4 2024 and a floor of $62.5 million in Q1 2021.
  • Historically, Current Assets has averaged $179.9 million across 4 years, with a median of $172.3 million in 2023.
  • The widest YoY moves for Current Assets: up 197.94% in 2021, down 36.87% in 2021.
  • Tracing KALV's Current Assets over 4 years: stood at $264.3 million in 2021, then crashed by 51.33% to $128.6 million in 2023, then surged by 122.37% to $286.0 million in 2024, then dropped by 15.49% to $241.7 million in 2025.
  • Business Quant data shows Current Assets for KALV at $241.7 million in Q2 2025, $286.0 million in Q4 2024, and $152.3 million in Q4 2024.